FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 307 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Teclistamab ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Making the most of your ‘eureka’ moment: getting from the science... September 22, 2021 Women and girls in science: We won’t stop pushing for progress February 11, 2023 News digest – targeted radiation beam, precision medicine and our early... October 17, 2020 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma July 31, 2020 Load more HOT NEWS Research with integrity – why building networks is vital for integrity MAP Congress 2020: Molecular Analysis for Precision Oncology Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients... How Does Smoking Increase Your Cancer Risk? An Expert Q&A
